The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal HemoglobinuriaPeter Hillmen, Lucio Luzzatto, Modupe Elebute et al.|New England Journal of Medicine|2006Cited by 1.3k
Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuriaRobert A. Brodsky, Peter Hillmen, Neal S. Young et al.|Blood|2007Cited by 653
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuriaPeter Hillmen, Neal S. Young, Petra Muus et al.|Blood|2007Cited by 578
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)Benjamin Hanfstein, Marc Müller, Rüdiger Hehlmann et al.|Leukemia|2012Cited by 417
Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IVAlice Fabarius, Armin Leitner, Andreas Hochhaus et al.|Blood|2011Cited by 289